Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935911 | 0.94 | HDAC1 (0.41) | HDAC1NR1H2USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL16989567 | 0.90 | USP2 (0.43) | HDAC1NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL6024437 | 0.88 | ESR2 (0.46) | NR1H2USP2SMN1; SMN2ALDH1A1ESR2 | |
| SCHEMBL9910665 | 0.88 | ESR2 (0.46) | NR1H2USP2SMN1; SMN2ALDH1A1ESR2 | |
| SCHEMBL6024434 | 0.88 | ESR2 (0.46) | NR1H2USP2SMN1; SMN2ALDH1A1ESR2 | |
| SCHEMBL20660348 | 0.85 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2ALDH1A1ESR2 | |
| SCHEMBL19342171 | 0.85 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2ALDH1A1ESR2 | |
| SCHEMBL106354 | 0.84 | USP2 (0.46) | NR1H2USP2SMN1; SMN2ALDH1A1ESR2 | |
| SCHEMBL23748406 | 0.83 | USP2 (0.43) | HDAC1NR1H2USP2SMN1; SMN2ESR2 | |
| SCHEMBL16995873 | 0.83 | USP2 (0.43) | HDAC1NR1H2USP2SMN1; SMN2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20220073518-A1 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-03-10 | — | — | US | disclosed |
| US-11198695-B2 | Fused ring derivative having MGAT-2 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2021-10-26 | — | — | US | disclosed |
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-01-28 | — | — | US | disclosed |
| CN-106488915-B | Cyclopropylamines as LSD1 inhibitors | 因赛特公司 | 2020-10-02 | — | — | CN | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073518-A1 | FUSED RING DERIVATIVE HAVING MGAT-2 INHIBITORY ACTIVITY | MGAT2, MGAT1, SOAT2 | HDAC1 404/4885NR1H2 88/4885USP2 1690/4885 |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | HDAC1 2777/4885NR1H2 3045/4885USP2 1614/4885 |
| US-20210024487-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HDAC1 66/4885NR1H2 409/4885USP2 422/4885 |
| US-11155532-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HDAC1 66/4885NR1H2 409/4885USP2 422/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | HDAC1 684/4885NR1H2 3062/4885USP2 2536/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | HDAC1 503/4885NR1H2 945/4885USP2 1176/4885 |
| US-11198695-B2 | Fused ring derivative having MGAT-2 inhibitory activity | MGAT2, MGAT1, SOAT2 | HDAC1 404/4885NR1H2 88/4885USP2 1690/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | HDAC1 503/4885NR1H2 945/4885USP2 1176/4885 |
| US-12024519-B2 | Fused ring derivative having MGAT-2 inhibitory activity | MGAT2, MGAT1, ACAT2 | HDAC1 437/4885NR1H2 89/4885USP2 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.